论文部分内容阅读
目的探讨莫西沙星在支原体肺炎中的治疗价值。方法选取我院在2013年6月至2015年1月收治的102例支原体肺炎患者的临床资料,将患者随机分为两组,各51例,对照组给予红霉素治疗,观察组采用莫西沙星治疗,比较两组患者的治疗效果、退热时间、肺部阴影X线消失时间、止咳时间。结果 1观察组有50例患者治疗有效,总有效率为98.04%。对照组有41例患者治疗有效,总有效率为80.39%,比较有统计学意义(P<0.05)。2观察组的肺部阴影X线消失时间、止咳时间与退热时间均短于对照组,比较有统计学意义(P<0.05)。结论支原体肺炎患者通过给予莫西沙星治疗,临床治疗有效率明显提升,病情改善时间缩短,值得临床推广应用。
Objective To investigate the therapeutic value of moxifloxacin in mycoplasma pneumonia. Methods The clinical data of 102 patients with mycoplasma pneumonia admitted in our hospital from June 2013 to January 2015 were selected and randomly divided into two groups, 51 cases in each group. The control group was treated with erythromycin, and the observation group was treated with moxisaban Star treatment, the treatment effect of two groups were compared, antipyretic time, pulmonary shadow disappearance of X-ray time, cough time. Results 1 The observation group of 50 patients were treated effectively, the total effective rate was 98.04%. The control group of 41 patients with effective treatment, the total effective rate was 80.39%, compared with statistical significance (P <0.05). 2 The observation group’s lung shadow X-ray disappearing time, cough-relieving time and anti-fever time were shorter than the control group, with statistical significance (P <0.05). Conclusion Mycoplasma pneumonia patients treated by moxifloxacin, clinical treatment efficiency was significantly improved, the condition to improve the time shortened, worthy of clinical application.